hd third training course final2
DESCRIPTION
TRANSCRIPT
![Page 1: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/1.jpg)
1
![Page 2: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/2.jpg)
2
Jafar Al-Said. M.B.CHB. MD. FASN. FACP.Chair of Internal Medicine.Nephrology and Internal Medicine Consultant.Bahrain Specialist Hospital.
Hemodialysis Patient Care
![Page 3: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/3.jpg)
3
Scheme • Epidemiology of ESRD.• Demographics of ESRD.• Anemia.• CVD.• Adequacy.• Mineral Bone Disorders. • Other parameters
![Page 4: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/4.jpg)
4
Epidemiology of ESRD population
![Page 5: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/5.jpg)
5
Comparison of unadjusted ESRD incidence worldwide. USRDS 2013
All rates are unadjusted. Data from Japan are dialysis only.
![Page 6: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/6.jpg)
6
Comparison of unadjusted ESRD prevalence worldwide. USRDS 2013
All rates are unadjusted. Data from Japan are dialysis only.
![Page 7: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/7.jpg)
7
Geographic variations in the incidence of ESRD (per million population), 2011
Data presented only for countries from which relevant information was available. All rates unadjusted. Latest data for Taiwan are for 2010. Data for France include 25 regions. Data for Belgium do not include patients younger than 20.
??
![Page 8: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/8.jpg)
8
![Page 9: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/9.jpg)
9
![Page 10: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/10.jpg)
10
![Page 11: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/11.jpg)
11
![Page 12: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/12.jpg)
12
Data presented only for countries from which relevant information was available; “.” signifies data not reported. All rates unadjusted. ^UK: England, Wales, & Northern Ireland (Scotland data reported separately). Data for Belgium do not include patients younger than 20. *Latest data for Taiwan are from 2010. Incident data for Croatia start at day 91, 2011. Data for France include 25 regions in 2011. All rates are unadjusted.
Incidence of ESRD, 2011GULF ?BAHRAIN ?Middle East?
![Page 13: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/13.jpg)
Prevalence of ESRD, 2011
![Page 14: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/14.jpg)
14
Percentage of incident patients with ESRD due to diabetes, 2011
Data presented only for countries from which relevant information was available. All rates unadjusted. ^UK: England, Wales, & Northern Ireland (Scotland data reported separately). *Latest data for Taiwan are from 2010. ^^ Czech Republic: Data on incident ESRD due to diabetes is an estimate. Data for France include 25 regions in 2011. .
![Page 15: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/15.jpg)
15
Percent distribution of prevalent dialysis patients, by modality, 2011
Data presented only for countries from which relevant information was available; “.” signifies data not reported. All rates unadjusted. ^UK: England, Wales, & Northern Ireland (Scotland data reported separately). **Data for Belgium do not include patients younger than 20. *Latest data for Taiwan are from 2010. Data for France include 25 regions in 2011.
![Page 16: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/16.jpg)
16
Patient counts, by modality
Incident & December point prevalent ESRD patients. CMS Annual Facility Survey.
![Page 17: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/17.jpg)
17
Incident & prevalent patient counts (USRDS), by modality
Incident & December 31 point prevalent ESRD patients; peritoneal dialysis consists of CAPD & CCPD.
![Page 18: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/18.jpg)
18
Adjusted prevalent rates of ESRD & annual percent change
December 31 point prevalent ESRD patients. Adj: age/gender/race; ref: 2010 ESRD patients.
![Page 19: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/19.jpg)
19
Incident counts & adjusted rates of ESRD, by primary diagnosis
Incident ESRD patients. Adj: age/gender/race; ref: 2010 ESRD patients.
![Page 20: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/20.jpg)
20
Prevalent counts & adjusted rates of ESRD, by primary diagnosis
December 31 point prevalent ESRD patients. Adj: age/gender/race; ref: 2010 ESRD patients.
Prevalence of ESRD
![Page 21: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/21.jpg)
21
Prevalent counts & adjusted rates of ESRD, by age
December 31 point prevalent ESRD patients. Adj: gender/race; ref: 2010 ESRD patients.
![Page 22: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/22.jpg)
22
DOPPsDialysis Outcomes and Practice Patterns Study
Australia, Bahrain, Belgium, Canada, China, France, Germany, Italy, Japan, Kuwait, New Zealand, Oman, Qatar, Russia, Saudi Arabia, Spain, Sweden, Turkey, the United Arab Emirates, the United Kingdom, and the United States
![Page 23: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/23.jpg)
23
Demographics of ESRD population
![Page 24: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/24.jpg)
24
DOPPS 4 (2011) Age, by country
The top and bottom of the boxes above indicate the 25th and 75th percentiles of the distribution. The horizontal line within the box indicates the median (50th percentile), and the diamond indicates the mean. Vertical lines extend to the 5th and 95th percentiles.
Median 67.74 y
![Page 25: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/25.jpg)
25
DOPPS 4 (2011) Body-mass index, by country
Median 25.3
![Page 26: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/26.jpg)
26
DOPPS 4 (2011) Male sex, by country
Male 60%
![Page 27: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/27.jpg)
27
DOPPS 4 (2011) Race/ethnicity, by country
![Page 28: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/28.jpg)
28
Anemia
![Page 29: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/29.jpg)
29
DOPPS 4 (2011) Hemoglobin, by country
Excludes patients with Hgb<4 g/dl or Hgb>18 g/dlThe top and bottom of the boxes above indicate the 25th and 75th percentiles of the distribution. The horizontal line withinthe box indicates the median (50th percentile), and the diamond indicates the mean. Vertical lines extend to the 5th and 95th percentiles.
Median 11.2
![Page 30: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/30.jpg)
30
DOPPS 4 (2011) Darbepoetin use, by country
Prescription in previous three months, among patients prescribed any ESA
Mean 40%
![Page 31: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/31.jpg)
31
DOPPS 4 (2011) Iron use (IV or oral), by country
Medications reported as prescribed in previous three months, among all patients
Mean 73.8%
![Page 32: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/32.jpg)
32
DOPPS 4 (2011) Serum ferritin, by country
The top and bottom of the boxes above indicate the 25th and 75th percentiles of the distribution. The horizontal line within the box indicates the median (50th percentile), and the diamond indicates the mean. Vertical lines extend to the 5th and 95th percentiles.
Median 406
![Page 33: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/33.jpg)
33
Patient distribution, by mean monthly hemoglobin (g/dl): hemodialysis patients
Period prevalent hemodialysis patients.
![Page 34: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/34.jpg)
34
Mean hemoglobin at initiation, by pre-ESRD ESA treatment
Incident ESRD patients.
![Page 35: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/35.jpg)
35
Hemodialysis patients receiving transfusions, by race
Incident hemodialysis patients. (Each month includes patients with a claim for hemodialysis.)
![Page 36: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/36.jpg)
36
Cardiovascular Disease
![Page 37: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/37.jpg)
37
DOPPS 4 (2011) Coronary artery disease, by country
Mean 33.5%
![Page 38: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/38.jpg)
38
DOPPS 4 (2011) Cerebrovascular disease, by country
Mean 14.5%
![Page 39: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/39.jpg)
39
DOPPS 4 (2011) Diabetes, by country
Mean 42%
![Page 40: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/40.jpg)
40
DOPPS 4 (2011) Diabetes as Cause of ESRD, by country
Mean 34.9%
![Page 41: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/41.jpg)
41
DOPPS 4 (2011) Hypertension, by country
Mean 85%
![Page 42: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/42.jpg)
42
DOPPS 4 (2011) Peripheral vascular disease, by country
Mean 28.6%
![Page 43: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/43.jpg)
43
USRDS 2013Cardiovascular Disease in ESRD population.
![Page 44: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/44.jpg)
44
Causes of death in prevalent dialysis patients, 2009-2011
Incident & prevalent dialysis patients, 2009–2011.
42%
![Page 45: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/45.jpg)
45
Survival of patients with cardiovascular diagnoses & procedures, by modality, 2009–2011
January 1 point prevalent ESRD patients, 2009, with a first cardiovascular diagnosis or procedure in 2009–2011.
![Page 46: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/46.jpg)
47
Rates of a CHF diagnosis in ESRD patients
Point prevalent ESRD patients on January 1 of each year: unadjusted.
![Page 47: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/47.jpg)
49
Rates of an AMI event in ESRD patients
Point prevalent ESRD patients on January 1 of each year: unadjusted.
![Page 48: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/48.jpg)
50
Percent of incident dialysis patients receiving first echocardiograms, 2011
Incident dialysis patients, 2011.
![Page 49: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/49.jpg)
51
Hemodialysis Adequacy
![Page 50: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/50.jpg)
52
DOPPS 4 (2011) Serum creatinine, by country
Median 8mg/dl
![Page 51: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/51.jpg)
53
DOPPS 4 (2011) Prescribed blood flow rate, by country
Replenishment sample patients only The top and bottom of the boxes above indicate the 25th and 75th percentiles of the distribution. The horizontal line within the box indicates the median (50th percentile), and the diamond indicates the mean. Vertical lines extend to the 5th and 95th percentiles .
Median 330
![Page 52: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/52.jpg)
54
DOPPS 4 (2011) Single-pool Kt/V, by country
Median 1.56
![Page 53: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/53.jpg)
55
Mineral Bone Disorders in ESRD
![Page 54: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/54.jpg)
56
Risk of all-cause mortality associated with combinations of baseline serum phosphorus and calcium categories by PTH level (from DOPPS)
Tentori F, et al. AJKD 52: 519, 2008
![Page 55: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/55.jpg)
57
Predialysis Multivariable-adjusted log hazards (solid lines) and 95% CI (dashed lines) of all-cause mortality associated with fixed baseline levels of serum calcium concentration in Cox
models
Kovesdy C P et al. CJASN 2010;5:468-476 ©2010 by American Society of Nephrology
Adjusted:• Age • Race• CrCl• DM• CVD• P• BMI• Smokin
g• PO
binders• Calcitri
ol• eGFR• HCO3• PO4• Alk.
Phosp.• Hb• WBC
![Page 56: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/56.jpg)
58
N = 16173 over 18 years
![Page 57: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/57.jpg)
59
N = 16173 over 18 years
![Page 58: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/58.jpg)
60
![Page 59: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/59.jpg)
61
![Page 60: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/60.jpg)
62
![Page 61: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/61.jpg)
63
![Page 62: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/62.jpg)
64
DOPPS 4 (2011) Total calcium, by country
Median 8.9
![Page 63: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/63.jpg)
65
DOPPS 4 (2011) Serum phosphorus, by country
3.5
5.5
Median 4.36
![Page 64: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/64.jpg)
66
DOPPS 4 (2011) Serum PTH, by country
300150
Mean 240
![Page 65: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/65.jpg)
67
DOPPS 4 (2011) Phosphate binder use, by country
Percent of patients prescribed any phosphate binder at end of study month, among all patients
Mean 80%
![Page 66: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/66.jpg)
68
DOPPS 4 (2011) Calcium-based phosphate binder, by country
Mean 38%
![Page 67: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/67.jpg)
69
DOPPS 4 (2011) Vitamin D use (IV or oral), by country
Mean 70%
![Page 68: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/68.jpg)
70
DOPPS 4 (2011) Serum albumin, by countryExcludes patients with albumin <1 g/dl or albumin >7 g/dl
Median 3.7
![Page 69: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/69.jpg)
71
Vaccination rates (percent), by age, race/ethnicity, & modality
ESRD patients initiating treatment at least 90 days before tracking period: September 1–December 31 for influenza, a two-year period for pneumococcal pneumonia, yearly for hepatitis B; patients alive on the period’s last day & vaccinations tracked during the period.
![Page 70: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/70.jpg)
72
Quality indicators: percentage of patients meeting clinical & preventive care guidelines
![Page 71: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/71.jpg)
73
Other Parameters for Care:• Monthly Serum K+.• Diabetic treatment.• HTN treatment. • Lipid profile.• Annual Cardiac evaluation. • Annual Dental care.• Medications review.• Regular meeting and interaction.• Diet Review.• Filter Clotting.
![Page 72: Hd third training course final2](https://reader033.vdocuments.mx/reader033/viewer/2022061120/546d75c6af795997388b6b03/html5/thumbnails/72.jpg)
74
Conclusion:ESRD patient would require high quality care to reduce the Mortality and Morbidity.
Different aspects of medical care if regularly evaluated.Vascular Access.• Anemia.• CVD.• DM• HTN• Hyperlipidemia • Mineral Bone Disorders.
• S. K.• Nutrition.• Vaccination.